1.

Gabutti V, Borgna-Pignatti C: Clinical manifestations and therapy of transfusional haemosiderosis.
Baillieres Clin Haematol 1994, 7:919-940. [PubMed Abstract] [Publisher Full Text]

Return to citation in text: [1]

2.

Ratip S, Skuse D, Porter J, Wonke B, Yardumian A, Modell B: Psychosocial and clinical burden of thalassaemia intermedia and its implications for prenatal diagnosis.
Arch Dis Child 1995, 72:408-412. [PubMed Abstract]

Return to citation in text: [1] [2] [3] [4]

3.

Caro JJ, Ward A, Green TC, Huybrechts K, Arana A, Wait S, Eleftheriou A: Impact of thalassemia major on patients and their families.
Acta Haematologica 2002, 107:150-157. [PubMed Abstract] [Publisher Full Text]

Return to citation in text: [1] [2] [3] [4] [5]

4.

Rebulla P: Transfusion reac tions in thalassemia. A survey from the Cooleycare programme. The Cooleycare Cooperative Group.
Haematologica 1990, 75:122-127. [PubMed Abstract]

Return to citation in text: [1]

5.

Giardina PJ, Grady RW: Chelation therapy in beta-thalassemia: an optimistic update.
Seminars in Hematology 2001, 38:360-366. [PubMed Abstract] [Publisher Full Text]

Return to citation in text: [1]

6.

Alymara V, Bourantas D, Chaidos A, Bouranta P, Gouva M, Vassou A, Tzouvara E, Bourantas KL: Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone.
Hematology Journal 5(6):475-9, 2004.

Return to citation in text: [1]

7.

Gabutti V, Piga A: Results of long-term iron-chelating therapy. [Review] [109 refs].
Acta Haematologica 1996, 91:26-36.

Return to citation in text: [1] [2]

8.

Porter JB: Deferoxamine pharmacokinetics.
Semin Hematol 2001, 38:63-68. [PubMed Abstract] [Publisher Full Text]

Return to citation in text: [1]

9.

Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher A: Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients.
Br J Haematol 2003, 121:187-189. [PubMed Abstract] [Publisher Full Text]

Return to citation in text: [1]

10.

Piga A: .
Bone Marrow Transplant 2001, 19:11-13.

Return to citation in text: [1]

11.

Shumaker SA, Berzon RA: The international assessment of HRQL. Theory, translations, measurement and analysis.. Oxford: Rapid Communications; 1995.

Return to citation in text: [1]

12.

Bowling A: Current state of the art in quality of life measurement.
In Quality of life. Edited by: Carr AJ, Higginson IJ and Robinson P. London, BMJ Books; 2003.

Return to citation in text: [1]

13.

Clarke S, Eiser C: The measurement of health-related quality of life (QOL) in pediatric trials: a systemic review.
2004, 6:66.

Return to citation in text: [1]

14.

Tefler P, Constantinidou G, Andreou P, Christou S, Modell B, Angastiniotis M: Quality of Life in Thalassaemia.
Annals of the New York Academy of Science 2005, 1054:273-282. [Publisher Full Text]

Return to citation in text: [1]

15.

Pakbaz Z, Treadwell M, Yamashita R, Quirolo K, Foote D, Quill L, Singer T, Vichinsky EP: Quality of Life in Patients with Thalassaemia Intermedia Compared to Thalassaemia Major.
New York Academy of Sciences 2005, 1054:457-461. [Publisher Full Text]

Return to citation in text: [1]

16.

Ismail A, Campbell MJ, Ibrahim HS, Jones GL: Health related quality of life in Malaysian children with thalassaemia.
Health and Quality of Life Outcomes 2006, 4:39. [BioMed Central Full Text]

Return to citation in text: [1]

17.

Anie KA, Steptoe A, Bevan DH: Sickle cell disease: Pain, coping and quality of life in a study of adults in the UK.
Br J Health Psychol 2002, 7:331-344. [PubMed Abstract] [Publisher Full Text]

Return to citation in text: [1] [2]

18.

Cummins O, Anie KA: A comparison of the outcome of cognitive behaviour therapy and hydroxyurea in sickle cell disease.
Psychol Health Med 2003, 8:199-204. [Publisher Full Text]

Return to citation in text: [1] [2]

19.

Fuggle P, Shand PA, Gill LJ, Davies SC: Pain, quality of life, and coping in sickle cell disease.
Arch Dis Child 1996, 75:199-203. [PubMed Abstract]

Return to citation in text: [1] [2]

20.

Hasan SP, Hashmi S, Alhassen M, Lawson W, Castro O: Depression in sickle cell disease.
Journal of the National Medical Association 2003, 95:533-537. [PubMed Abstract]

Return to citation in text: [1] [2] [3]

21.

Palermo TM, Schwartz L, Drotar D, McGowan K: Parental report of health-related quality of life in children with sickle cell disease.
J Behav Med 2002, 25:269-283. [PubMed Abstract] [Publisher Full Text]

Return to citation in text: [1] [2]

22.

Thomas VJ, Hambleton I, Serjeant G: Psychological distress and coping in sickle cell disease: comparison of British and Jamaican attitudes.
Ethn Health 2001, 6:129-136. [PubMed Abstract] [Publisher Full Text]

Return to citation in text: [1] [2]

23.

Thomas VJ, Taylor LM: The psychosocial experience of people with sickle cell disease and its impact on quality of life: Qualitative findings from focus groups.
Br J Health Psychol 2002, 7:345-363. [PubMed Abstract] [Publisher Full Text]

Return to citation in text: [1] [2]

24.

Jansen AJ, Essink-Bot ML, Beckers EA, Hop WC, Schipperus MR, Van Rhenen DJ: Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes.
Br J Haematol 2003, 121:270-274. [PubMed Abstract] [Publisher Full Text]

Return to citation in text: [1] [2]

25.

Kornblith AB, Herndon JE, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF, Powell BL, DeCastro C, Ellerton J, Larson RA, Schiffer CA, Holland JC: Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.
Journal of Clinical Oncology 2002, 2441-2452. [PubMed Abstract] [Publisher Full Text]

Return to citation in text: [1] [2] [3]

26.

Sekeres MA, Stone RM, Zahrieh D, Neuberg D, Morrison V, De Angelo DJ, Galinsky I, Lee SJ: Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome.
Leukemia 2004, 18:809-816. [PubMed Abstract] [Publisher Full Text]

Return to citation in text: [1] [2] [3]

27.

Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.
J Clin Oncol 2002, 20:2429-2440. [PubMed Abstract] [Publisher Full Text]

Return to citation in text: [1] [2]

28.

Arboretti R, Tognoni G, Alberti D, Thalassarmia ICG: Pharmacosurveillance and quality of care of thalassaemic patients. A large scale epidemiological survey.
European Journal of Clinical Pharmacology 2001, 56:915-922. [PubMed Abstract] [Publisher Full Text]

Return to citation in text: [1] [2] [3]

29.

Smiley M: Beta thalassaemia in Papua New Guinea.
Ann Trop Paediatr 1986, 6:175-177. [PubMed Abstract]

Return to citation in text: [1] [2]

30.

Basran RK, Fasson FF, Shaw D, Olivieri NF: Assessment of the relative quality of life in patients receiving subcutaneous deferoxamine and the orally active iron chelating agent L1.
Blood 1994, 84:261a.

Return to citation in text: [1]

31.

Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M, Galanello R, Fattoum S, Drelichman G, Magnano C, Verissimo M, Athanassiou-Metaxa M, Giardina P, Kourakli-Symeonidis A, Janka-Schaub G, Coates T, Vermylen C, Olivieri N, Thuret I, Opitz H, Ressayre-Djaffer C, Marks P, Alberti D: A Phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with {beta}-thalassemia.
Blood 2005., .:

Return to citation in text: [1]

32.

Poole JE, Cohn RJ, Roode H, Spector I: Beta-thalassaemia--the Johannesburg experience.
S Afr Med J 1989, 75:367-370. [PubMed Abstract]

Return to citation in text: [1]